Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/ritonavir for severe COVID-19 in hospitalized patients (EPIC-HOS)
NCT05545319Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Planned start Dec 2022; status: withdrawn.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05545319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545319.